MHI-RJ-AVIATION-GROUP
20.7.2022 18:34:04 CEST | Business Wire | Press release
MHI RJ Aviation Group (MHIRJ) has announced today at the Farnborough Air Show the signing of an agreement with Air Nostrum Engineering and Maintenance (ANEM), appointing them as a MHIRJ Authorized Service Facility (ASF) in Europe. This agreement marks an important step in expanding MHIRJ’s service network internationally, allowing MHIRJ to extend, in collaboration with ANEM, the same levels of service that customers in North America receive through its wholly owned service centers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220720005641/en/
This agreement expands MHIRJ’s existing ASF support structure in Europe, introducing diversity and additional capacity to the existing network. ANEM’s addition will serve to meet the growing demands of the market, offering a wider array of availability and options for the European sector as well as for MHIRJ customers worldwide.
Based in Valencia (Spain), ANEM is part of the group of companies fully owned by the same shareholders of the airline Air Nostrum. ANEM currently serves as MRO and aircraft maintenance services provider for multiple airlines based in Europe, Africa, and Latin America. Air Nostrum has been operating CRJ Series aircraft since the year 1998 and currently operates the largest CRJ Series fleet in Europe, accounting for 37 CRJ Series aircraft. Air Nostrum is a ten-time MHIRJ Customer Reliability Award winner and a multiple time winner of the ERA Airline of the Year. Their vast operational experience will provide a first-rate base to support the CRJ Series fleet in Europe and across the world. Combining the strengths of ANEM and MHIRJ will bring forth our world-class Aftermarket network to the next level, providing our customers the full suite of MRO services.
Hiro Yamamoto, President and CEO of MHIRJ, commented “We are extremely proud to announce this agreement with Air Nostrum which will benefit customers in the European region, allowing them to access strong MRO support close to home. Reliability has always been the CRJ Series fleet’s strong suit; this agreement maintains that reliability and ensures an even stronger commitment to our customers.”
“ANEM brings a versatile set of capabilities that substantially enhances the CRJ Series MRO support for our European and International customers. As the maintenance arm of the largest CRJ Series carrier in Europe; our strategic collaboration with ANEM favorably positions us to collectively grow and expand support outside of North America,” commented Ismail Mokabel, Senior Vice-President and Head of Aftermarket at MHIRJ.
Amel Belkhamsa, Head of Aftermarket Commercial Services and Spare Parts Operations at MHIRJ, added “This is the first step in broadening our relationship with Air Nostrum to provide support to MHIRJ’s customers outside of North America. We wanted to find an MRO with a large range of capabilities to open the door to even more potential future collaboration, such as in the areas of material support and field response services, to ensure that all our international customers receive the best support available.”
Miguel Falcon, Vice Chairman of Air Nostrum and ANEM, said: “We are delighted to strengthen our cooperation with MHIRJ via this ASF agreement as its next Authorized MRO. We have 24 years of experience with the CRJ Series and have provided exceptional reliability for our customers, and this is due largely to the great relationship that we have with MHIRJ.”
Fermin Tirado, General Manager of ANEM, commented: “Thanks to the dedication and exceptional skills of our team members at ANEM, we´re quite pleased to sign this ASF agreement with MHIRJ that enhances our long-established partnership, allows us to increase the number of employees in ANEM, and grow our capacity for our airline customers.”
About Air Nostrum Group
Air Nostrum Group comprises different companies related to air transport and mobility including airlines, high speed railway transportation and firefighting, as well as related services companies: maintenance, training, flight support etc. The Group flagship, Air Nostrum Líneas Aereas, based in Spain, operates over 70,000 flights carrying more than 4,7 million passengers each year, being the leading regional aviation company in Spain and one of the largest in Europe. It operates for the Iberia Group under the Iberia Regional Air Nostrum brand, has sales over 500 million euros and employs more than 1,400 people.
About ANEM
ANEM is a PART 145 MRO (ES.145.060) and CAMO (ES.CAMO.059) company that arises from the split of AIR NOSTRUM’s business activities. ANEM performs the whole maintenance of the Air Nostrum’s Group fleets, including Air Nostrum, Hibernian, Melair, Paranair and PLYSA. These fleets are: CRJ200, CRJ900, CRJ1000, ATR72-600, and THRUSH S2R-T660. ANEM has a modern Hangar in Valencia Airport in order to cover all maintenance phases of the Air Nostrum’s Group and other operators’ fleets.
About MHI RJ Aviation Group
MHI RJ Aviation Group (MHIRJ) provides comprehensive critical operational, engineering and customer support solutions including maintenance, refurbishment, technical publications, marketing and sales activities for the global regional aircraft industry. Headquartered in Montréal, Canada, and bolstered by an Aerospace Engineering Centre, MHIRJ’s network of service centers, support offices and parts depots are positioned in important aviation hubs in Canada, the U.S. and Germany. A wholly owned subsidiary of Mitsubishi Heavy Industries, Ltd., MHI RJ Aviation Group includes MHI RJ Aviation ULC (Canada), MHI RJ Aviation Inc. (U.S.A.) and MHI RJ Aviation GmbH (Germany).
WE ARE HIRING. Visit mhirj.com/en/careers to know more.
For more information about MHI RJ Aviation Group, please visit: mhirj.com or follow our insights and stories on wingspan.mhirj.com
About MHI Group
Mitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, logistics & infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life, and ensure a safer world.
For more information, please visit www.mhi.com or follow our insights and stories on www.spectra.mhi.com
*CRJ, CRJ Series and MHIRJ are trademarks of MHI RJ Aviation ULC or its affiliates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220720005641/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom